{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:25:04Z","timestamp":1791509104560,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.arbres.2025.12.008","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:42:26Z","timestamp":1767976946000},"page":"717-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["New Perspectives in the Treatment of Bronchiectasis"],"prefix":"10.1016","volume":"62","author":[{"given":"Angela","family":"Tramontano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagiovanna","family":"Caporaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Macciocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Simonetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.arbres.2025.12.008_bib0335","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","article-title":"Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations","volume":"10","author":"Aliberti","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.arbres.2025.12.008_bib0340","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00518-2024","article-title":"Bronchiectasis management in adults: state of the art and future directions","volume":"63","author":"Choi","year":"2024","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0345","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00081-2015","article-title":"The EMBARC European Bronchiectasis Registry: protocol for an international observational study","volume":"2","author":"Chalmers","year":"2016","journal-title":"ERJ Open Res"},{"issue":"174","key":"10.1016\/j.arbres.2025.12.008_bib0350","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0091-2024","article-title":"Epidemiology of bronchiectasis","volume":"33","author":"Nigro","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"16","key":"10.1016\/j.arbres.2025.12.008_bib0355","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.arbres.2025.12.008_bib0665","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1164\/rccm.202408-1545OC","article-title":"Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial","volume":"211","author":"Johnson","year":"2025","journal-title":"Am J Respir Crit Care Med."},{"issue":"6","key":"10.1016\/j.arbres.2025.12.008_bib0670","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01126-2025","article-title":"European Respiratory Society clinical practice guideline for the management of adult bronchiectasis","volume":"66","author":"Chalmers","year":"2025","journal-title":"Eur Respir J."},{"issue":"4","key":"10.1016\/j.arbres.2025.12.008_bib0370","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-0041-1730891","article-title":"Pathophysiology of bronchiectasis","volume":"42","author":"Keir","year":"2021","journal-title":"Semin Respir Crit Care Med"},{"issue":"173","key":"10.1016\/j.arbres.2025.12.008_bib0375","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0055-2024","article-title":"Pathophysiology and genomics of bronchiectasis","volume":"33","author":"Perea","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"10150","key":"10.1016\/j.arbres.2025.12.008_bib0380","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0385","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4046\/trd.2024.0120","article-title":"Disease severity and activity in bronchiectasis: a paradigm shift in bronchiectasis management","volume":"88","author":"Im","year":"2025","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"11","key":"10.1016\/j.arbres.2025.12.008_bib0390","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1164\/rccm.202303-0499OC","article-title":"Inflammatory molecular endotypes in bronchiectasis: a european multicenter cohort study","volume":"208","author":"Choi","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0395","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.202310-1729OC","article-title":"Endotypes of exacerbation in bronchiectasis: an observational cohort study","volume":"210","author":"Gao","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.arbres.2025.12.008_bib0675","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J."},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0405","article-title":"British Thoracic Society guideline for bronchiectasis in adults","volume":"5","author":"Hill","year":"2018","journal-title":"BMJ Open Respir Res"},{"issue":"7","key":"10.1016\/j.arbres.2025.12.008_bib0410","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","article-title":"Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)","volume":"11","author":"Chalmers","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.arbres.2025.12.008_bib0415","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.arbres.2025.12.008_bib0420","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S2213-2600(24)00225-X","article-title":"Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months","volume":"12","author":"Haworth","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0680","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur Respir J."},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0430","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2 a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.arbres.2025.12.008_bib0435","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.arbres.2025.12.008_bib0440","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.arbres.2025.12.008_bib0445","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0450","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2022.07.007","article-title":"A double-blind randomized placebo-controlled phase 3 trial of tobramycin inhalation solution in adults with bronchiectasis with Pseudomonas aeruginosa infection","volume":"163","author":"Guan","year":"2023","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0455","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12931-022-02243-y","article-title":"Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis","volume":"23","author":"Terpstra","year":"2022","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0460","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01451-2020","article-title":"Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study","volume":"57","author":"Loebinger","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0465","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chest.2024.01.045","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: updated systematic review and meta-analysis","volume":"166","author":"Cordeiro","year":"2024","journal-title":"Chest"},{"issue":"Abstracts","key":"10.1016\/j.arbres.2025.12.008_bib0470","doi-asserted-by":"crossref","first-page":"A3117","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A3117","article-title":"A bispecific monoclonal antibody targeting Psl and PcrV for chronic Pseudomonas aeruginosa infection in patients with bronchiectasis: results from a randomized double-blind placebo-controlled trial (GREAT-2)","volume":"211","author":"Long","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0475","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1164\/rccm.202308-1403OC","article-title":"A bispecific monoclonal antibody targeting Psl and PcrV enhances neutrophil-mediated killing of Pseudomonas aeruginosa in patients with bronchiectasis","volume":"210","author":"Long","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"176","key":"10.1016\/j.arbres.2025.12.008_bib0480","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0179-2024","article-title":"Neutrophilic inflammation in bronchiectasis","volume":"34","author":"Chalmers","year":"2025","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2025.12.008_bib0485","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00081-2025","article-title":"Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target","author":"Chalmers","year":"2025","journal-title":"Eur Respir J"},{"issue":"22","key":"10.1016\/j.arbres.2025.12.008_bib0490","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0685","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01551-2024","article-title":"Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study","volume":"65","author":"Chalmers","year":"2025","journal-title":"Eur Respir J."},{"issue":"8","key":"10.1016\/j.arbres.2025.12.008_bib0500","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1164\/rccm.202108-1889OC","article-title":"Characterization of eosinophilic bronchiectasis: a European multicohort study","volume":"205","author":"Shoemark","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.arbres.2025.12.008_bib0505","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.arbres.2022.12.008","article-title":"Biologics in bronchiectasis: a future treatment?","volume":"59","author":"Nigro","year":"2023","journal-title":"Arch Bronconeumol"},{"issue":"12","key":"10.1016\/j.arbres.2025.12.008_bib0510","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S2213-2600(14)70213-9","article-title":"The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial","volume":"2","author":"Rogers","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"9842","key":"10.1016\/j.arbres.2025.12.008_bib0515","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.arbres.2025.12.008_bib0520","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.arbres.2025.12.008_bib0525","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.arbres.2025.12.008_bib0530","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.arbres.2025.12.008_bib0535","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1513\/AnnalsATS.201601-044OC","article-title":"Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non-cystic fibrosis bronchiectasis: an analysis from the bronchiectasis and low-dose erythromycin study trial","volume":"13","author":"Burr","year":"2016","journal-title":"Annals ATS"},{"issue":"3","key":"10.1016\/j.arbres.2025.12.008_bib0540","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01574-2024","article-title":"Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis","volume":"65","author":"Guo","year":"2025","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.arbres.2025.12.008_bib0545","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/thorax-2024-221825","article-title":"Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)","volume":"80","author":"Pollock","year":"2025","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2025.12.008_bib0550","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.01079-2024","article-title":"Dual Bronchodilators in Bronchiectasis Study (DIBS): a randomised controlled trial","author":"Wilson","year":"2025","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0555","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","article-title":"Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease","volume":"163","author":"Rabe","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.arbres.2025.12.008_bib0560","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind placebo-controlled, multicenter phase III trials (the ENHANCE trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.arbres.2025.12.008_bib0565","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01689-2023","article-title":"Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)","volume":"63","author":"Spinou","year":"2024","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.arbres.2025.12.008_bib0570","doi-asserted-by":"crossref","first-page":"00426","DOI":"10.1183\/23120541.00426-2021","article-title":"4-Week daily airway clearance using oscillating positive-end expiratory pressure versus autogenic drainage in bronchiectasis patients: a randomised controlled trial","volume":"7","author":"Livnat","year":"2021","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0575","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01926-2017","article-title":"Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial","volume":"51","author":"Mu\u00f1oz","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.arbres.2025.12.008_bib0580","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00962-2024","article-title":"Impact of long-term high-flow nasal therapy on mucus plugs in patients with bronchiectasis","volume":"11","author":"Crimi","year":"2025","journal-title":"ERJ Open Res"},{"issue":"24","key":"10.1016\/j.arbres.2025.12.008_bib0585","doi-asserted-by":"crossref","first-page":"7323","DOI":"10.3390\/jcm11247323","article-title":"Long-term domiciliary high-flow nasal therapy in patients with bronchiectasis: a preliminary retrospective observational case\u2013control study","volume":"11","author":"Crimi","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0590","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1186\/s13063-019-3766-9","volume":"20","author":"Bradley","year":"2019","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0595","article-title":"Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trial","volume":"11","author":"Chang","year":"2024","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0600","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27471","article-title":"Reconsidering the diagnosis: abnormal sweat chloride tests in non-CF bronchiectasis","volume":"60","author":"Huang","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.arbres.2025.12.008_bib0605","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00007-2025","article-title":"Efficacy of elexacaftor\u2013tezacaftor\u2013ivacaftor in non-cystic fibrosis bronchiectasis patients with a single pathogenic CFTR mutation: a retrospective cohort analysis","author":"Papadakis","year":"2025","journal-title":"ERJ Open Res"},{"issue":"11","key":"10.1016\/j.arbres.2025.12.008_bib0610","article-title":"Autologous transplantation of P63+ lung progenitor cells in patients with bronchiectasis: a randomized, single-blind, controlled trial","volume":"5","author":"Yan","year":"2024","journal-title":"Cell Rep Med"},{"issue":"3","key":"10.1016\/j.arbres.2025.12.008_bib0615","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00408-022-00540-3","article-title":"Effects of pulmonary rehabilitation on systemic inflammation and exercise capacity in bronchiectasis: a randomized controlled trial","volume":"200","author":"Ara\u00fajo","year":"2022","journal-title":"Lung"},{"issue":"17","key":"10.1016\/j.arbres.2025.12.008_bib0620","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191711039","article-title":"Exercise capacity and physical activity in non-cystic fibrosis bronchiectasis after a pulmonary rehabilitation home-based programme: a randomised controlled trial","volume":"19","author":"Cede\u00f1o de Jes\u00fas","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"10.1016\/j.arbres.2025.12.008_bib0625","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1465-9921-15-44","article-title":"The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis \u2013 a randomised controlled trial","volume":"15","author":"Lee","year":"2014","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.arbres.2025.12.008_bib0630","doi-asserted-by":"crossref","first-page":"00021","DOI":"10.1183\/23120541.00021-2021","article-title":"Home-based pulmonary rehabilitation in people with bronchiectasis: a randomised controlled trial","volume":"7","author":"Jos\u00e9","year":"2021","journal-title":"ERJ Open Res"},{"issue":"12","key":"10.1016\/j.arbres.2025.12.008_bib0635","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.rmed.2012.08.004","article-title":"A pilot study of pulmonary rehabilitation and chest physiotherapy versus chest physiotherapy alone in bronchiectasis","volume":"106","author":"Mandal","year":"2012","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.arbres.2025.12.008_bib0640","doi-asserted-by":"crossref","DOI":"10.21037\/jtd-2024-1945","article-title":"Phenotypes and endotypes in bronchiectasis: a narrative review of progress toward precision medicine","volume":"17","author":"Choi","year":"2025","journal-title":"J Thorac Dis"},{"issue":"6","key":"10.1016\/j.arbres.2025.12.008_bib0645","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.chest.2025.07.4087","article-title":"Inflammatory and mucociliary dysfunction-based endotypes across the spectrum of chronic airway diseases","volume":"168","author":"Cant","year":"2025","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.arbres.2025.12.008_bib0650","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jcf.2024.03.008","article-title":"ECFS standards of care on CFTR-related disorders: identification and care of the disorders","volume":"23","author":"Simmonds","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.arbres.2025.12.008_bib0655","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00007-2025","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in non-cystic fibrosis bronchiectasis patients with a single pathogenic CFTR mutation: a retrospective cohort analysis","volume":"11","author":"Papadakis","year":"2025","journal-title":"ERJ Open Res"},{"issue":"11","key":"10.1016\/j.arbres.2025.12.008_bib0660","article-title":"Autologous transplantation of lung progenitor cells comes into reality for bronchiectasis","volume":"5","author":"Yue","year":"2024","journal-title":"Cell Rep Med"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:38:31Z","timestamp":1790869111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289626000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0300289626000049"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2025.12.008","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Perspectives in the Treatment of Bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2025.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}